c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial
Robert D. Morgan,
Cristina Ferreras,
Isabel Peset,
Egle Avizienyte,
Andrew G. Renehan,
Richard J. Edmondson,
Alexander D. Murphy,
Shibani Nicum,
Thomas Van Brussel,
Andrew R. Clamp,
Diether Lambrechts,
Cong Zhou,
Gordon C. Jayson
Affiliations
Robert D. Morgan
Division of Cancer Sciences, Faculty of Biology, Health and Medicine, University of Manchester
Cristina Ferreras
Division of Cancer Sciences, Faculty of Biology, Health and Medicine, University of Manchester
Isabel Peset
Medicines Discovery Catapult
Egle Avizienyte
Cancer Communications and Consultancy Ltd.
Andrew G. Renehan
Division of Cancer Sciences, Faculty of Biology, Health and Medicine, University of Manchester
Richard J. Edmondson
Division of Cancer Sciences, Faculty of Biology, Health and Medicine, University of Manchester
Alexander D. Murphy
The Christie NHS Foundation Trust
Shibani Nicum
Oxford University Hospitals NHS Foundation Trust
Thomas Van Brussel
Leuven Center for Cancer Biology, University of Leuven
Andrew R. Clamp
Division of Cancer Sciences, Faculty of Biology, Health and Medicine, University of Manchester
Diether Lambrechts
Leuven Center for Cancer Biology, University of Leuven
Cong Zhou
Cancer Biomarker Centre, Cancer Research UK Manchester Institute
Gordon C. Jayson
Division of Cancer Sciences, Faculty of Biology, Health and Medicine, University of Manchester
Highlights Tissue microarrays and germline DNA from women recruited to the phase 3 trial, ICON7, underwent quantitative immunofluorescence for c-MET/VEGFR-2 co-expression and genetic sequencing for single nucleotide polymorphisms (SNPs) VEGF-pathway genes. High c-MET/VEGFR-2 co-localisation on tumour tissue independently predicted worse survival in bevacizumab-treated epithelial ovarian cancer. The VEGFR-2 rs2305945 SNPs also independently predict worse survival in bevacizumab-treated epithelial ovarian cancer.
